Serum biomarkers of collagen metabolism, pyridinoline (PYD) and aminoterminal properptide of type i procollagen (PINP) as diagnostic staging markers of bone metastases in breast cancer patients.

Iles, Ray K., Cheung, Kwok-Leung, Robertson, John and Perrett, David (2010) Serum biomarkers of collagen metabolism, pyridinoline (PYD) and aminoterminal properptide of type i procollagen (PINP) as diagnostic staging markers of bone metastases in breast cancer patients. Tumour Biology, 31 (S72) . ISSN 1010-4283 [Article]

Abstract

Aims: Breast cancers frequently metastasise to bone and early assessment of the extent of disease is important in therapy decision. We examined whether serum biomarkers of bone formation and destruction could aid or replace bone scans. Methods: The serum concentrations of the bone resorption marker pyridinoline (PYD) and the bone formation
marker aminoterminal propeptide of type I procollagen (PINP) were measured in 200 breast cancer patients at different stages of disease. Results: Both biomarkers showed
elevated levels when bone was involved with median PYD concentrations 1.9 times and PINP 3.2 times higher than those found in an age matched control group. However, PYD
concentrations increased steadily with the extent to which breast tumours invaded surrounding tissue. Conclusions: PYD is also released from basement membrane collagen
thus elevation is also due to soft tissues destroyed by the breast lesion and not just from destruction of bone collagen. However, PINP concentrations were only significantly elevated in patients with bone metastases. Thus, PINP appears to be a superior serum biomarker of bone metastases and may prove useful for monitoring or indeed
pre-screening patients for bone metastases and hence reducing the number of bone scans.

Actions (login required)

View Item

Statistics

DownloadsShow export options

Export as CSVXMLJSON

Activity Overview

6 month trend

0Downloads

6 month trend

426Hits

Additional statistics are available via IRStats2.